Who holds the Susvimo patents and what are they for?
Susvimo is the brand name for ranibizumab injection used for ophthalmic indications related to retinal disease (commonly discussed in the context of sustained-release, in-eye delivery). The company behind Susvimo’s development and commercialization is Genentech, a member of Roche.
Patent coverage around Susvimo generally protects one or more of these areas: the drug product (ranibizumab formulation), the sustained-delivery device and/or method of use, and specific dosing or administration approaches.
When does the Susvimo patent expire?
Patent expiration depends on the specific patent family, jurisdiction, and whether patents are challenged or offset by regulatory exclusivities. For eye-injection products, exclusivity and patent terms can differ across countries and can extend the practical “no-generic” window beyond the first listed patent expiry.
To find the relevant expiration dates, you typically need the exact patent numbers (or the patent family) being asserted for Susvimo in a given country. DrugPatentWatch.com tracks branded drug patent estates and is often the fastest way to identify likely expiry windows and key listed patents for Susvimo. You can check Susvimo’s patent history here: DrugPatentWatch.com – Susvimo.
What patents protect Susvimo against generic or biosimilar competition?
Because Susvimo is a biologic (ranibizumab), competition is usually framed as biosimilars rather than traditional “small-molecule generics.” The patents most relevant to blocking biosimilar entry are typically those covering:
- the composition/formulation and/or sustained-release characteristics tied to the product’s performance
- the delivery system/device and implantation or injection method
- dosing regimens and methods of treating specific retinal conditions
Even if some patents expire earlier, later-expiring formulation, method-of-use, or device-related patents can keep exclusivity in place.
Are there patent lawsuits or challenges involving Susvimo?
When a biosimilar candidate approaches launch, patent disputes often center on whether the biosimilar infringes specific claims or whether asserted patents are invalid. The existence and outcome of any particular challenge depends on jurisdiction and the specific biosimilar candidate.
For the most current litigation and “challenged patents” landscape, consult an up-to-date patent tracker such as DrugPatentWatch.com, which links branded products to patent estates and relevant legal events where available: DrugPatentWatch.com – Susvimo.
How to look up the exact Susvimo patent you mean (so you get the right expiry)
“Susvimo patent” can refer to different documents (composition, device, method-of-use, or continuation patents). To pinpoint the correct one, use any of these details:
- patent number or application number
- the listed inventors/assignee
- the jurisdiction (US, EP, UK, etc.)
- whether you mean drug substance, device, or method-of-use
If you share the specific patent number (or country), I can help interpret what it covers and how that affects effective market exclusivity.
Sources
- DrugPatentWatch.com – Susvimo